Summary In this session, Terrie Moffitt, professor at Duke University, and Daniel Belsky, assistant professor at Columbia University, dove into the details of a new approach to measuring aging using DNA methylation. Their Pace of Aging approach, based on which a second generation DunedinPACE algorithm was developed, looks at multiple timepoints and assesses how fast… Continue reading Daniel Belsky, Terrie Moffitt | The DunedinPoAm DNA Methylation Algorithm
Summary In this session, Michael Snyder, Professor in Genetics at Stanford University, reported the latest findings from their longitudinal trials of healthy people being profiled using various omics and wearables. The first part was focused on the necessity of collecting a healthy personal baseline, because the differences between people are much larger than significant variations… Continue reading Michael Snyder, Stanford University | Monitoring Personal Health and Ageotypes Using Big Data
Summary In this session, Michael Levin, director of the Tufts Center for Regenerative and Developmental Biology, introduced the field of bioelectricity, and the impressive regenerative potential it harbors. Michael showcased techniques that enable regrowth of limbs and formation of different organs using bioelectricity and cocktails of repurposed ion channel drugs. And he also gave an… Continue reading Bioelectric Networks: Taming the Collective Intelligence of Cells for Regenerative Medicine
Summary In this session, Daniel Ives, founder of Shift Bioscience, introduced their transcriptomic driver clock which enabled them to identify putative drug targets for safer cellular rejuvenation, which might avoid the challenges coupled to therapeutic use of Yamanaka factors. Daniel goes into detail on what the clock enables, how they are planning to validate these… Continue reading Drug Target Discovery for Cellular Rejuvenation by ‘Driver’ Clocks | Daniel Ives, Shift Bioscience
Summary In this session, Nir Barzilai, professor at Albert Einstein School of Medicine and director of Institute for Aging Research, presented the current state of the groundbreaking TAME trial serving as a framework and data springboard for the whole longevity field, as well as the future plans for other TAME-like trials with other drugs with… Continue reading TAME Q&A: Lessons for Progress on Aging | Nir Barzilai, Albert Einstein School of Medicine
Summary In this session, Keith Murphy, founder of Organovo and CEO and founder of Viscient Biosciences, covered the recent developments in the field of 3D tissue bioprinting and human organ models on a chip or sometimes also called patient trials in a dish. He went into the different technologies that are being used and trialed,… Continue reading ”Patient Trials in a Dish” Paths Forward | David Gobel, Methuselah, Keith Murphy, Organovo
Summary In this session, Morgan Levine, Assistant Professor at Yale, gave a sneak peek into the new epigenetic clock they are developing that is able to probe into multiple organ systems, as well as on a new approach how to calculate clocks that is much more reliable, enabling to generate insights from methylation clocks with… Continue reading Biomarker Standardization | Morgan Levine, Yale, Jamie Justice, Wake Forest School of Medicine
Summary In this session, Steve Horvath, professor at the University of California Los Angeles, provided an overview of the current state of the epigenetic clock field and the new developments in it. Then he went on to talk about what is missing in regards to methylation clocks and the longevity field itself, as well as… Continue reading EpigeneticClocks: What’s New & What’s Missing? | Steve Horvath, UCLA
Summary In this session, Gordan Lauc (Genos Glyco & GlycanAge) and Vadim Gladyshev (Harvard), gave their point of view on biomarkers & aging clocks development. Gordan Lauc went through the interesting glycomic data they recently and insights it generated about aging and menopause, exceptional predictive capability of glycans for hypertension, and much more. Vadim Gladyshev… Continue reading Biomarker & Aging Clock Development | Vadim Gladyshev, Harvard, Gordan Lauc, GlycanAge
Summary In this session, Alex Zhavoronkov, CEO and Founder of Insilico Medicine and Deep Longevity, offered his roadmap for what he calls Longevity as a Service. He explained the approach Deep Longevity and Young.ai are taking, the various clocks and machine learning methods they are using, the necessity for physician education and coordinated building of… Continue reading Longevity as a Service: AI & Aging Clocks | Alex Zhavoronkov, Deep Longevity & Insilico Medicine
